Unlike most other drugs, advanced therapies require complex, purpose-built supply chain networks. Making them requires cross-sector collaboration.
- 5 QMS Blind Spots You Should Know About
- New MIT Consortium Links Innovation With Real-World Biomanufacturing
- Injecting Cancer Killers: Intratumoral Therapy For Solid Tumors
- Proteomics Tools: A Resurrection
- Powering AI And Synthetic Biology In Therapy Design
- Six Specialized Modalities Testing CDMO Readiness In 2026
- Green Supply Chains Rarely Start With A Pledge; Target Waste Instead
- The Real Reason We Haven't Fully Automated Cell Therapy Yet
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Reframing Clinical Vendor Selection
Explore a platform that enables seamless vendor selection as well as cross-functional collaboration with built-in templates and tailored question libraries that simplify proposal creation and review.
-
A Scalable Manufacturing Platform For The Purification Of Stem Cell Derived Exosomes
EV production scale increases require paired robust, scalable, and cost-effective downstream processes. Process parameters can be tailored for therapeutic exosome programs and allow for maximum exosome recovery.
-
Assessing The Success Of CRISPR Gene Therapies Using ddPCR Technology
Achieve high-fidelity results in gene therapy research. Discover how absolute quantification overcomes traditional limitations to provide the precision needed for validating CRISPR edits.
-
Revolutionizing Lentiviral Vector Manufacturing For In Vivo, Ex Vivo CAR-T Therapies
Discover how scalable, cost-effective, and high-quality lentiviral vector manufacturing can accelerate both ex vivo and emerging in vivo CAR-T therapies.
-
Risk Assessment Services Align With FDA Guidance For Gene-Edited Human Gene Therapy Products
Navigate the FDA's gene therapy guidelines with advanced risk assessment strategies. Optimize gene editing and ensure regulatory alignment for safer, more effective therapies.
-
Rapid, Seamless Upstream Process Development And Scale-Up For CHO-K1 Cells
Accelerate your biotech company's scale-up process while delivering consistent and strong cell growth, productivity, and product quality.
-
Improve Speed To Market By Mitigating Vial And Stopper Incompatibility
These studies indicate that with a properly assembled vial containment system, good CCI performance can be achieved with stoppers of a given elastomer, independent of configuration/size, or vial style.
-
Mycoplasma Testing In Monoclonal Antibody Production
Prevent costly disruptions in your bioproduction process. Discover how a PCR-based method can quickly detect the presence of mycoplasmas in raw materials, cell banks, and in-process and lot-release samples.
-
IVT mRNA Encapsulation Efficiency Assessment
In vitro transcribed mRNA revolutionizes biotherapeutics, which necessitates thorough quality assessments. See how an analyzer system enhances encapsulation efficiency and CQAs in IVT mRNA workflows.
-
12-Day Stability Of PRIME-XV T Cell Expansion Supplemented With CTGrade GMP Cytokines
Discover how T-cell culture media supplemented with key cytokines can maintain full functionality and support robust expansion for up to 12 days at room temperature.
NEWSLETTER ARCHIVE
- 03.11.26 -- Are You Scaling CGT Wrong?
- 03.11.26 -- Regulators Maintain Consistent Endpoints While Raising Evidence Standards
- 03.10.26 -- STREAM Edition: mRNA Hot Takes: Fighting Complacency And "Alternative Facts" In 2026
- 03.10.26 -- The Real Reason We Haven't Fully Automated Cell Therapy Yet
- 03.09.26 -- Putting Pressure On CDMOs With Herman Bozenhardt
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections